Views & Analysis | Perspectives on pharma industry issues

Oncology

pharmaphorum podcast Episode 282 at ESMO26: Dr Chuck Link, Syncromune

ESMO26: Lowering toxicity, extending lives, with Syncromune

As the ESMO26 Congress commences in Madrid, pharmaphorum invited Syncromune Executive Chairman Dr Chuck Link onto the podcast.

Oncology

Why precision biomarkers will change the future of breast ca...

Blood-based biomarkers can provide an earlier, dynamic view of what is happening inside a patient, creating an opportunity to detect changes sooner.

Sales & Marketing

Benefits of marketing with AI tools, upward trajectory graph

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Oncology

Sponsored

12 Questions with Julia Jakl

Learn more about Julia Jakl, VP and Business Unit Head, Oncology UK at GSK, in a new 12 Questions With.

Market Access

Sponsored

The pre-commercial case for connecting data before acquiring...

For EBPs, launch requires a data strategy that starts with agreement on the KPIs, and those depend on the therapeutic areas.

Articles

Patient perspective interview series: overview

Following the theme of patients this month, Rebecca Aris summarises pharmaphorum’s patients perspective interview series to date and highlights some common thoughts. Having spoken with many different patients on their experiences with the healthcare industry and on what...

Articles

Cystinosis: one family’s journey with a rare disease

Our focus this month is on rare diseases. Here, one mother shares her story about how the introduction of the Orphan Drug Act 1983 changed her son’s life, and many other lives, for the better. My husband and I did not notice the passage of the Orphan Drug Act in 1983. We were new parents immersed in the…

Articles

How to supply drugs to remote areas of the globe

Melissa Russell discusses the challenges in supplying drugs to remote areas of the world and how pharma can best overcome these issues. When most people think about global health crises, impediments to remote pharmaceutical distribution typically aren’t…

Sales & Marketing

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Sales & Marketing

Building a social presence inside regulatory guardrails

In the UK, promoting prescription-only medicines to the public is prohibited by law and by the ABPI Code - social media reactions and shares included.

Digital

Sponsored

Why AI transformation is really about people

Jeff Kaminski, global head of AI and data at Axtria and a former industry analyst, discusses culture, governance, and leadership challenges around AI.

Digital